



Mithra Releases Invitation to its General Ordinary and Extraordinary Securities holders' Meeting

Liege, Belgium, 19 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health today announces the invitation to its ordinary and extraordinary securities holders' meeting that will be held on **Thursday May 19 2022 at 2:00 PM (CEST)**.

The notice for the General Meeting including a description of the formalities to participate in the Meeting is available on the website investors.mithra.com.

Exceptional organisational arrangements due to Covid-19

Considering the COVID-19 pandemic, it is possible that our governments and public authorities may adapt the conditions and modalities for physical participation in the General Meeting. We reserve our rights to issue additional instructions in this regard. These measures are in the interest of the health of the individual security holders, as well as of the Company's employees and other persons responsible for organizing the General Meeting. Therefore, the Company recommends that shareholders of the Company who wish to participate in the General Meeting use, to the extent possible, the right to vote by mail or by proxy containing specific voting instructions for each proposed decision granted to Fanny Rozenberg, Secretary of the Board of Directors of the Company, and not to attend the General Meeting personally. The Company will grant access to the General Meeting to security holders, proxy holders and any other persons only to the extent permitted by the measures taken or to be taken by the authorities, as applicable at the time of the General Meeting, and always taking into account the recommendations of the authorities, as well as safety and health considerations. In addition, holders of the Company's securities are encouraged to exercise their right to ask questions in writing concerning the items on the agenda of the General Meeting. Details of how to participate in the Ordinary Shareholders' Meeting are set out in this notice of meeting. The Company will also set up a videoconference to enable holders of the Company's securities who have duly registered for the General Meeting and who have duly completed and returned the notice of participation to the Company to follow the General Meeting remotely.

Videoconferencing will not be considered as an electronic means of communication to attend and vote at the General Meeting, as referred to in Article 7:137 of the Companies and Associations Code but will be an additional means for the security holders to follow the General Meeting. The Company will closely monitor the situation and applicable actions and may provide further updates relevant or impacting the Ordinary General Meeting on the Company's website: investors.mithra.com.

All procedures for attending the ordinary and extraordinary shareholders' meetings are indicated in the present meeting's invitation.

Admission requirements

As referred in the meeting's invitation published in the Belgian press, the right to participate in the general shareholder's meeting and to vote is subject to the prior registration of the shares under the shareholder's name on **5 May 2022 at midnight (CEST) (the "Record Date")**, either by way of registration on the company's share register, or either by way of registration in book entry form in an account held

with a settlement institution or a certified account holder, without taking into account the number of shares held by the shareholder at the day of the general meeting. Only persons who are shareholders on the Record Date are entitled to vote at the general meeting.

A certification is delivered to the shareholder by the settlement institution or certified account holder which certifies the number of dematerialized shares registered in its accounts under the name of the shareholder on the Record Date, for which the shareholder has expressed its intention to participate in the general meeting.

The shareholder indicates his willingness to participate in the General Meeting by **13 May 2022** at the latest. This must be done by email to corporate.secretary@mithra.com, or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège.

Right to ask questions

The directors answer questions that are asked by the shareholders, in writing before the meeting, concerning their report or the agenda, in accordance with legal provisions. These questions may be asked prior to the General Meeting by email to the address corporate.secretary@mithra.com or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège. These questions must be received by the Company on **13 May 2022** at the latest.

Further information relating to the abovementioned right and the modalities for exercising them are available on the Company's website (www.mithra.com).

Proxies

Any shareholder who wish to vote for that meeting shall be represented by a proxy holder determined by the Company.

Shareholders wishing to be represented must send the completed and signed¹ proxy form to the Company on **13 May 2022** at the latest, by email, fax or mail to Mithra's headquarter.

Shareholders wishing to vote by mail must send the completed and signed¹ proxy form to the Company on **13 May 2022** at the latest, by email, fax or mail to Mithra's headquarter.

Further information on the exercise of this right is available on the Company's website (www.mithra.com). The proxy and voting forms may be obtained on the Company's website (www.mithra.com) or upon request at the Company's registered office, or by email to corporate.secretary@mithra.com.

Shareholders wishing to be represented must comply with the registration and confirmation procedure described above.

Available documents

All documents concerning the general meeting that are required by law to be made available to shareholders as well as the text of the amended articles of association following the approval of the amendments proposed on the agenda may be consulted on the Company's website (www.mithra.com) as from 19 April 2022. As from the same date, shareholders have the right to consult these documents on business days and during normal office hours, at the Company's registered office and/or, upon display of their securities, obtain copies of these documents free of charge.

¹ The form must be signed in writing or electronically, with a qualified electronic signature within the meaning of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended

Requests for copies may also be made, free of charge, by mail (writing) marked for the attention Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège, or by email to corporate.secretary@mithra.com.

For more information, please contact:

Benoît Mathieu (IRO) : +32 473 35 80 18 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, Mithra is now focusing on its second product Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium.

www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates", "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

News
Alerts

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)